DeCure for Rhizomelic chondrodysplasia punctata type 1
DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for rhizomelic chondrodysplasia punctata type 1 — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleRhizomelic chondrodysplasia punctata type 1 maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for rhizomelic chondrodysplasia punctata type 1 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
Rhizomelic chondrodysplasia punctata type 1 is a rare, severe skeletal disorder. A 1971 description in German defined the rhizomelic form as a lethal, probably autosomal-recessively inherited genopathy with specific radiographic features: symmetrical, severe shortening of the femur and/or humerus; pronounced metaphyseal ossification disturbances; epiphyseal and extra-epiphyseal calcification foci in the first year of life, with later epiphyseal ossification anomalies; vertical, systemic ossification clefts of the vertebral bodies; and trapezoid dysplasia of the iliac wings. The authors assigned 33 literature cases and 9 of their own observations to this type. A 2003 case report of a 52-day-old child described rhizomelic micromelia, characteristic facies, suction difficulty, and anthropometric measures below expected. Skeletal radiographs showed humeral and femoral shortening and stippled calcifications at the shoulders, hips, and knees. The patient also had a heart malformation, noted as a less common manifestation. The authors stated that only 72 cases had been reported up to 1995, that prognosis is bad, and that death usually occurs within the first year of life.
A 1987 study identified rhizomelic chondrodysplasia punctata as a peroxisomal disorder. The authors stated that most patients die young, some survive into their teens, but all are severely retarded. They noted that peroxisomal investigations may be important for defining prognosis in an individual patient and are definitely useful for antenatal diagnosis. A 2019 update on morbidity and mortality was published, but the abstract provides no numerical data on survival, response rates, or sample sizes; it only lists conflicts of interest and notes that the data are available from the corresponding author upon reasonable request.
What is still missing is a large, prospective natural history study with published quantitative outcomes. The 2019 update is mentioned but its results are not given in the abstract. No treatment trials are reported in these abstracts. There is no information on patient stratification by genotype or biochemical subtype, and no funding for a therapy trial is described.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren · 1971 · 22 citations
Chondrodysplasia punctata (Chondrodystrophia calcificans) II. Der rhizomele Typ<sup>*</sup>
AbstractDie rhizomele Form der Chondrodysplasia punctata ist eine letale, wahrscheinlich autosomal-rezessiv vererbte Genopathie mit folgenden röntgenologischen Merkmalen: 1. Symmetrische, schwere Verkürzung von Femur und/oder Humerus. 2. Ausgeprägte metaphysäre Ossifikationsstörungen. 3. Epiphysäre und extraepiphysäre Verkalkungsherde im ersten Lebensjahr, spätere epiphysäre Ossifikationsanomalien. 4. Vertikale, systemhafte Ossifikationsspalten der Wirbelkörper. 5. Trapezförmige Dysplasie der Beckenschaufeln. Die Merkmale 1, 2, 4 und 5 werden nur bei dieser Form der Chondrodysplasia punctata angetroffen. Ihre Differenzierung von der Conradi-Hünermannschen Form der Chondrodysplasia punctata ist aus pathogenetischen, prognostischen und genetischen Gründen erforderlich. Dem rhizomelen Typ der Chondrodysplasie punctata werden 33 Literaturfälle und 9 eigene Beobachtungen zugeordnet.
American Journal of Medical Genetics Part A · 2019 · 21 citations · open access
Rhizomelic chondrodysplasia punctata morbidity and mortality, an update
AbstractDr. Michael Bober is a PI for A Prospective Natural History Study of Patients with Rhizomelic Chondrodysplasia Punctata, sponsored by Med-Life Discoveries LP. Dr. Michael Bober, Dr. Nancy Braverman, and Dr. Poll-Thé are also members of Medical Advisory Board for RhizoKids International. The other authors have no conflict of interest to declare. The data that support the findings of this study are available from the corresponding author upon reasonable request.
Jornal de Pediatria · 2003 · 11 citations · open access
Condrodisplasia puntiforme forma rizomélica: relato de caso
AbstractOBJECTIVE: To report a case of rhizomelic chondrodysplasia punctata and present a brief literature review. DESCRIPTION: The authors report the case of a 52-day-old child presenting the main findings of the syndrome: rhizomelic micromelia, characteristic facies, suction difficulty and anthropometric measures below the expected indexes for his age. Skeletal radiographies showed humeri and femora shortening and calcifications stippling on shoulders, hips and knees joints. The patient also presented heart malformation, a less common manifestation of the syndrome. COMMENTS: The rhizomelic form of chondrodysplasia punctata is rare, with only 72 cases reported until 1995. The prognosis is bad and death usually occurs within the first year of age. The case presented here was diagnosed based on clinical and radiological criteria, due to the impossibility of searching for the peculiar biochemical markers.
Ophthalmic Paediatrics and Genetics · 1987 · 8 citations
Peroxisomal dysfunction in chondrodysplasia punctata, rhizomelic type
AbstractThe rhizomelic type of chondrodysplasia punctata (RCDP) is recognizable at birth because of the typical phenotype and radiological features. Most patients die young, some survive until their teens but all are severely retarded. Recent studies showed RCDP to be a peroxisomal disorder. Peroxisomal investigations may be important in defining the prognosis for an individual patient, and are definitely of use in antenatal diagnosis.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
